APhA depression management study
Executive Summary
American Pharmacists Association is launching a depression-management program to evaluate the effect of pharmacist-delivered medication therapy management-type services. Project ImPACT: Depression (Improving Persistence And Compliance with Therapy) will focus on whether pharmacists can improve depression treatent adherence. Project ImPACT has previously targeted hyperlipidemia and osteoporosis (1"The Pink Sheet" March 30, 1998, p. 20). Support for the depression study is provided by Wyeth, manufacturer of the serotonin/norepinephrine reuptake inhibitor Effexor XR (venlafaxine extended-release)...